BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

183 related articles for article (PubMed ID: 38791096)

  • 21. Effect of chemoradiotherapy on the proportion of circulating lymphocyte subsets in patients with limited-stage small cell lung cancer.
    Chen Y; Jin Y; Hu X; Chen M
    Cancer Immunol Immunother; 2021 Oct; 70(10):2867-2876. PubMed ID: 33674986
    [TBL] [Abstract][Full Text] [Related]  

  • 22. The evolving landscape of immunotherapy in small-cell lung cancer: A focus on predictive biomarkers.
    Gelsomino F; Lamberti G; Parisi C; Casolari L; Melotti B; Sperandi F; Ardizzoni A
    Cancer Treat Rev; 2019 Sep; 79():101887. PubMed ID: 31491661
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Expression and clinical significance of PD-L1, B7-H3, B7-H4 and TILs in human small cell lung Cancer (SCLC).
    Carvajal-Hausdorf D; Altan M; Velcheti V; Gettinger SN; Herbst RS; Rimm DL; Schalper KA
    J Immunother Cancer; 2019 Mar; 7(1):65. PubMed ID: 30850021
    [TBL] [Abstract][Full Text] [Related]  

  • 24. PIV and PILE Score at Baseline Predict Clinical Outcome of Anti-PD-1/PD-L1 Inhibitor Combined With Chemotherapy in Extensive-Stage Small Cell Lung Cancer Patients.
    Zeng R; Liu F; Fang C; Yang J; Luo L; Yue P; Gao B; Dong Y; Xiang Y
    Front Immunol; 2021; 12():724443. PubMed ID: 34777341
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Cocaine Use Disorder Is Associated With Changes in Th1/Th2/Th17 Cytokines and Lymphocytes Subsets.
    Zaparte A; Schuch JB; Viola TW; Baptista TAS; Beidacki AS; do Prado CH; Sanvicente-Vieira B; Bauer ME; Grassi-Oliveira R
    Front Immunol; 2019; 10():2435. PubMed ID: 31749792
    [No Abstract]   [Full Text] [Related]  

  • 26. Predictive value of peripheral regulatory T cells in non-small cell lung cancer patients undergoing radiotherapy.
    Liu C; Wu S; Meng X; Liu G; Chen D; Cong Y; Shen G; Sun B; Wang W; Wang Q; Gao H; Liu X
    Oncotarget; 2017 Jun; 8(26):43427-43438. PubMed ID: 28624781
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Predictive and prognostic value of folate receptor-positive circulating tumor cells in small cell lung cancer patients treated with first-line chemotherapy.
    Shen J; Zhao J; Jiang T; Li X; Zhao C; Su C; Zhou C
    Oncotarget; 2017 Jul; 8(30):49044-49052. PubMed ID: 28467771
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Galectin-9-based immune risk score model helps to predict relapse in stage I-III small cell lung cancer.
    Chen P; Zhang L; Zhang W; Sun C; Wu C; He Y; Zhou C
    J Immunother Cancer; 2020 Oct; 8(2):. PubMed ID: 33082168
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Immune phenotype of patients with stage IV metastatic inflammatory breast cancer.
    Fernandez SV; MacFarlane AW; Jillab M; Arisi MF; Yearley J; Annamalai L; Gong Y; Cai KQ; Alpaugh RK; Cristofanilli M; Campbell KS
    Breast Cancer Res; 2020 Dec; 22(1):134. PubMed ID: 33267869
    [TBL] [Abstract][Full Text] [Related]  

  • 30. CD8(high)CD57(+) T-cell population as an independent predictor of response to chemoradiation therapy in extensive-stage small cell lung cancer.
    Dobrovolskienė NT; Cicėnas S; Kazlauskaitė N; Mišeikytė-Kaubrienė E; Krasko JA; Ostapenko V; Pašukonienė V; Strioga MM
    Lung Cancer; 2015 Nov; 90(2):326-33. PubMed ID: 26319316
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Prolonging Survival: The Role of Immune Checkpoint Inhibitors in the Treatment of Extensive-Stage Small Cell Lung Cancer.
    Melosky B; Cheema PK; Brade A; McLeod D; Liu G; Price PW; Jao K; Schellenberg DD; Juergens R; Leighl N; Chu Q
    Oncologist; 2020 Nov; 25(11):981-992. PubMed ID: 32860288
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Meta-analysis of PD-(L)1 inhibitor plus chemotherapy versus chemotherapy as first-line treatment in extensive-stage small-cell lung cancer.
    Lu J; Lei X; Zhang P; Du L; Zhang Z; Qu B
    Cancer Med; 2023 Sep; 12(17):17924-17933. PubMed ID: 37563966
    [TBL] [Abstract][Full Text] [Related]  

  • 33. [Clinical Research Progress of Immune Checkpoint Inhibitors in the Treatment of 
Small Cell Lung Cancer].
    Huang B; Duan Y
    Zhongguo Fei Ai Za Zhi; 2019 Apr; 22(4):239-244. PubMed ID: 31014443
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Identification of Potential Prognostic and Predictive Biomarkers for Immune-Checkpoint Inhibitor Response in Small Cell Lung Cancer.
    Gao C; Gu X; Chen Y; Zhou M; Jiang F; Zheng S
    Med Sci Monit; 2021 Nov; 27():e932275. PubMed ID: 34719665
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Induction of Peripheral Effector CD8 T-cell Proliferation by Combination of Paclitaxel, Carboplatin, and Bevacizumab in Non-small Cell Lung Cancer Patients.
    de Goeje PL; Poncin M; Bezemer K; Kaijen-Lambers MEH; Groen HJM; Smit EF; Dingemans AC; Kunert A; Hendriks RW; Aerts JGJV
    Clin Cancer Res; 2019 Apr; 25(7):2219-2227. PubMed ID: 30642911
    [TBL] [Abstract][Full Text] [Related]  

  • 36. [Immunotherapy Advances in Small Cell Lung Cancer].
    Xu Y; Zhan P; Song Y
    Zhongguo Fei Ai Za Zhi; 2020 Nov; 23(11):989-998. PubMed ID: 32752583
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Targeting DNA Damage Response Promotes Antitumor Immunity through STING-Mediated T-cell Activation in Small Cell Lung Cancer.
    Sen T; Rodriguez BL; Chen L; Corte CMD; Morikawa N; Fujimoto J; Cristea S; Nguyen T; Diao L; Li L; Fan Y; Yang Y; Wang J; Glisson BS; Wistuba II; Sage J; Heymach JV; Gibbons DL; Byers LA
    Cancer Discov; 2019 May; 9(5):646-661. PubMed ID: 30777870
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Efficacy and safety of PD-L1 inhibitors versus PD-1 inhibitors in first-line treatment with chemotherapy for extensive-stage small-cell lung cancer.
    Yu H; Chen P; Cai X; Chen C; Zhang X; He L; Zhou Y; Hong S; Zhang B
    Cancer Immunol Immunother; 2022 Mar; 71(3):637-644. PubMed ID: 34297160
    [TBL] [Abstract][Full Text] [Related]  

  • 39. [Clinical significance of T lymphocyte subset changes after first line chemotherapy in peripheral blood from patients with advanced stage adenocarcinoma cell lung cancer].
    Yan X; Zhao X; Jiao S; Sun S; Wu L; Wu Z
    Zhongguo Fei Ai Za Zhi; 2012 Mar; 15(3):164-71. PubMed ID: 22429580
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Identification of a prognostic immune-related signature for small cell lung cancer.
    Xie Q; Chu H; Yi J; Yu H; Gu T; Guan Y; Liu X; Liang J; Li Y; Wang J
    Cancer Med; 2021 Dec; 10(24):9115-9128. PubMed ID: 34741430
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 10.